ANTI-PD-L1 HUMANIZED NANOBODY AND USE THEREOF

• Main Authors: MA, Xiaowei, PAN, Ruowen, AN, Wenqi, FAN, Bei, AN, Kang, ZHANG, Baoxian
• Format: Patent
• Language: Chinese; English; French
• Published: 27.12.2018
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

Provided are an anti-PD-L1 humanized nanobody and the use thereof. In particular, provided is a nanobody of an anti-protein programmed death ligand 1 (PD-L1). The anti-PD-L1 nanobody can effectively block the binding of PD-L1 to a programmed death molecule 1 (PD-1), and can thus successfully block the inhibitory effect of PD-L1 on T cells expressing PD-1. The PD-L1 nanobody can be applied to the prevention, diagnosis and treatment of PD-L1-related diseases. Further provided is a humanized PD-L1 nanobody sequence. The humanized nanobody still has the function of blocking the binding of PD-L1 to PD-1, and has high affinity and high specificity, and can be used as an antibody drug for a tumor immunity target site. L'invention concerne un nanocorps humanisé anti-PD-L1 et une utilisation correspondante. En particulier, l'invention concerne un nanocorps d'un anti-ligand 1 protéinique de mort programmée (PD-L1). Le nanocorps anti-PD-L1 peut bloquer efficacement la liaison de PD-L1 à une molécule de mort programmée 1